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Summary Most monoclonal antibodies that have been raised to human epithelial tumours bind to only some
of the cells in a tumour, showing that tumour cells are very heterogenous in their expression of antigens.
Normal epithelia show the same heterogeneity of antigen expression, as also do cell lines and clones of
epithelial cells in culture. It is not related to the mitotic cell cycle. Many, probably most of the antigenic
determinants to which the antibodies bind are carbohydrate structures. It is not clear whether variations in
antigen expression reflect variations in the differentiated state of the cells or merely variations in the
carbohydrate structures on otherwise identical cells, nor is ir clear whether antibodies could be made that
bind to all tumour cells by avoiding antibodies to carbohydrate structures. The normal and apparently
reversible nature of this heterogeneity of antigen expression conflicts with conventional views that
heterogeneity among cells of a tumour is due to permanent genetic change. The heterogeneity within normal
clones suggests that cloning is not an adequate way to study heterogeneity in tumour cells. The implications
of heterogeneous expression of antigens within tumours for therapeutic and diagnostic application of
antibodies are discussed.
Many laboratories have been raising monoclonal
antibodies to cell-surface antigens of human
epithelia and epithelial tumours in the hope of
applying them to the diagnosis, detection and
therapy of malignancy (reviews: monoclonal
antibodies in general, Edwards, 1981; used in
pathology, Neville et al., 1982; Damjanov &
Knowles, 1983; in therapy, Levy & Miller, 1983;
antigens on tumour cells, Lloyd, 1983). Perhaps the
most interesting observation that has come out of
this work is that when a tumour or normal
epithelium is stained with a given antibody only
some of the cells in the tumour or epithelium bind
the antibody. In other words, the antibodies appear
to define distinct populations of cells in normal and
neoplastic epithelia. This clearly poses problems for
therapy and diagnosis, as a given antibody will only
bind detectably to a proportion of cells in a given
tumour.
In this review I have attempted to summarise
what we know and do not know about this
phenomenon and its biological significance, and to
discuss its implications not only for the
development of antibody therapy and diagnosis,
but also for the study of the cellular heterogeneity
of tumours.
The illustrations are taken from work of this
laboratory purely for convenience and the
advantages of colour. As far as I am aware the
general phenomena of staining that are illustrated
are similar to those obtained with the antibodies
raised in other laboratories.
The observations
Most monoclonal antibodies to epithelial tumours
stain the cells of a tumour heterogeneously
Typically, when a section through a tumour is
stained with a monoclonal antibody, some cells are
positive while others of apparently identical
morphology are negative. Representative examples
are shown in Figures 1 and 2. It seems that the
great majority of monoclonal antibodies raised to
epithelial tumours behave like this. Of the
inonoclonal antibodies raised to breast tumours,
the majority have been reported to show
heterogeneity (Arklie et al., 1981; Colcher et al.,
1981; Ellis et al., 1984; Foster et al., 1982a, b;
Hilkens et al., 1984). Of other anti-breast
antibodies that have been tested on sections of
tumour, it is not stated whether staining is
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Legend to Colour Plate
Examples ofheterogeneous antigen expression by tumours, normal epitheliuin and cloned cells in culture.
For convenience these examples were obtained using the author's monoclonal antibodies, but they are
representative of the antibodies in the field.
Figures 1 and 2 Typical staining of tumour sections by monoclonal antibodies. Some cells are positive,
others, apparently of the same morphology, are negative. In (1) the distribution of positive cells is scattered,
in (2) whole areas of tumour are positive or negative. Conventional paraffin sections were stained by the
immunoperoxidase method which produces a brown reaction product where antibody has bound. Blue is a
haemalum counterstain to show nuclei. Monoclonal antibody LICR-LON-M8 (Foster et al., 1982b) on breast
carcinoma. (1) x 200; (2) x 80. (Courtesy ofDr P. Monaghan and J.D.B. Roberts).
Figures 3 to 5 Antigenic heterogeneity in normal epithelia, demonstrated by two-colour immunofluorescence
(Edwards & Brooks, 1984 and unpublished). (3) Normal endometrium, which displays an apparently random
pattern of antigens. The tissue was stained intact and unfixed, as a sheet, and is viewed en face, not in
section. Each patch of colour is the apical membrane of an individual cell. Monoclonal antibodies LICR-
LON-M8 (green fluorescence) and LICR-LON-M24 (red fluorescence). Yellow cells are those stained by both
antibodies, x 300. (4) Normal breast duct epithelium, which shows reproducible, recognisable patterns of
antigen expression. Stained as a sheet of tissue obtained by dissecting out a duct and splitting it along its
length (Edwards & Brooks, 1984). Viewed en face, not in section, as in (3), x 300. Antibodies and colours as
in (3). (5) Frozen section of normal human colon, where antigen expression seems to be linked to the
maturation of the cells. Staining by antibody LICR-LON-M8 (in green) seems concentrated in the crypts, and
as the cells pass up the crypts they increasingly express antigen LICR-LON-M24 (red). Antibodies and
colours as in (3) and (4), x 70. Figure 6 Antigenic heterogeneity in a single-cell clone of normal breast
epithelial cells, showing that heterogeneity is rapidly regenerated in clones. Normal breast epithelium cells
were obtained by digestion with collagenase (Easty et al., 1980) then trypsin +EDTA. Single cells were
isolated by micromanipulation to ensure single-cell origin of the clones (Zagury et al., 1981), and grown on a
sparse feeder layer in petri dishes (Stoker et al., 1982). Monoclonal antibodies LICR-LON-M8 (green) and
LICR-LON-M24 (red), x 200.ANTIGENIC HETEROGENEITY OF TUMOUR CELLS 151152 P.A.W. EDWARDS
heterogeneous, e.g. MBrl and MOvI (Menard et
al., 1983), but experience with these antibodies,
many of which have now been exchanged between
laboratories, shows that it usually will be. Colon
(Arends et al., 1983; Daar & Fabre, 1982; Finan et
al., 1982) and lung (Wagenaar et al., 1984) tumours
also show heterogeneity. In melanoma antibodies
shown to stain heterogeneously include Me4-TB7,
C13-C6 and Nu4B (Carrel et al., 1982; Thompson
et al., 1982) as well as antibodies to HLA-DR as
discussed below. The antibody SSEA-1 shows
heterogenous staining of colon, stomach and kidney
carcinoma, although breast carcinoma was almost
homogeneously positive (Fox et al., 1983). The
antibody Cal (McGee et al., 1982) stains various
tumours heterogeneously. These are only examples
- many more have been reported. The antigens are
in most cases membrane antigens although in
tumours they often appear in the cytoplasm (Sloane
& Ormerod, 1981) perhaps because of accumulation
in membrane vesicles (Hilkens et al., 1984). Some
antigens are, however, clearly expressed in the
cytoplasm of normal cells and show heterogeneous
staining of tumours. These include a prostate
antigen described by Papsidero et al. (1983) and
certain cytokeratin antigens (Gatter & Mason,
1982; Ramaekers et al., 1983) as discussed in more
detail below.
The appearance of heterogeneous staining varies
(Hand et al., 1983; Wilkinson et al., 1984; Wright et
al., 1983). As illustrated in Figures 1 and 2, positive
and negative may be quite evenly mixed together,
or staining may be focal, or whole regions of a
tumour may be largely positive while other
apparently similar areas are negative. Some cells
may be stained predominantly in the cytoplasm,
while others will show clear membrane staining,
and this may be confined to a lumen or all around
the cells. Staining may also be extracellular. Wide
variations in the staining pattern will also be seen
between individual tumours of the same type, so
that tumours could be classified according to their
expression of particular antigens or staining
patterns (Hand et al., 1983; Wilkinson et al., 1984;
Rasmussen et al., 1982). One antibody will stain
one population of tumour cells while another
antibody, to a different antigen, may stain another
population (Foster et al., 1982a; Rasmussen et al.,
1982).
This last observation confirms that heterogeneity
in antigen expression is not just a "patchy staining"
artefact caused, for example, by uneven fixation. In
fact, the phenomenon can be demonstrated on
viable, unfixed tissue by two-colour immuno-
fluorescence, one antibody staining cells left
unstained by the other and vice versa (Figures 3-5).
Nor is heterogenous staining a peculiarity of
monoclonal antibodies - it was first seen with
polyclonal antisera such as rabbit antiserum to the
epithelial membrane antigen described by Ormerod
and co-workers (Sloane & Ormerod, 1981).
Not all surface antigens on tumour cells are
expressed heterogeneously - there are monoclonal
antibodies that stain tumour cells homogeneously,
that is, all the tumour cells express the antigen in
similar quantities, but they seem only to be
antibodies that do not have specificity for epithelial
cells or tumours. For example, Figure 7 contrasts
the heterogeneity in fluorescence of a breast tumour
cell line stained with a monoclonal antibody
specific for epithelial cells with the homogenous
fluorescence given by a monoclonal antibody that
binds to many types of adult human cell. Similarly,
the use of monoclonal antibodies to distinguish
between T and B lymphocytes and subsets of T
lymphocytes depends on the uniform, i.e.
homogenous, staining given by monoclonal
antibodies to these subsets such as OKT4 and
OKT8 (Greaves et al., 1981). There must be some
surface molecules present on all the cells of an
epithelium that ought to be homogeneously-
expressed, epithelium-specific antigens - certain
transport proteins perhaps. Nevertheless, the great
majority of monoclonal antibodies available at
present only bind to some of the cells.
Antigenic heterogeneity is a property ofnormal
epithelia
"Antigenic heterogeneity" is not just a property of
tumours but of a wide range of normal epithelia.
Many monoclonal antibodies to epithelial tumours
also stain the normal tissue well, and in general the
normal epithelium stains just as heterogeneously as
the tumours: a given antibody only stains some of
the normal cells and different antibodies stain
different populations of the cells. For example, in
breast, antibody HMFGI stains about 30% of
normal epithelial cells (Arklie et al., 1981) and in
colon some antibodies stain cells predominantly in
the crypts while others stain cells higher in the
crypts and on the luminal face (Daar & Fabre,
1983; Finaq et al., 1982). This is perhaps best
shown by two-colour immunofluorescence -
examples of different populations of epithelial cells
stained by different antibodies in normal epithelia
of breast, endometrium and colon are shown in
Figures 3-6 (Edwards & Brooks, 1984).
Antigenic heterogeneity is constantly regenerated in
clones, even ofnormal cells
Antigenic heterogeneity is also shown by cells in
culture, both in short term cultures of normal cells
and in long-established tumour cell lines (Chang &
Taylor-Papadimitriou, 1983; Hand et al., 1983;
Peterson et al., 1983; Edwards & Brooks, 1984).ANTIGENIC HETEROGENEITY OF TUMOUR CELLS
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Figure 7 The contrast between heterogeneous and homogeneous antigen expression on a tumour cell line
analysed by flow cytometry. The breast tumour cell line MCF7 was stained by immunofluorescence: in the
left-hand histogram with a monoclonal antibody LICR-LON-M8 to a heterogeneously-expressed antigen
found on epithelial cells and in the right-hand histogram with a monoclonal antibody LICR-LON-FIB75 to a
homogeneously-expressed antigen found on most human cells. The flow cytometer displays a histogram of the
number of cells having a particular strength of fluorescence. Thus, on the left, antibody M8 gives a
continuous curve tailing from many negative cells right out to a small number of intensely fluorescent cells,
while on the right, antibody FIB75 produces a distinct peak indicating that the cells are essentially all stained
to a similar extent.
Clones have been grown in monolayer culture to
see whether they are homogeneous in antigen
expression, from both normal breast epithelial cells
and breast tumour cell lines. Single cells grow into
clones displaying typical antigenic heterogeneity
(Stoker et al., 1982; Peterson et al., 1983). Figure 6
shows a typical, not extreme, example, from our
own work (Edwards et al., 1984a). Some cells in the
clone express one antigen, some express a second
antigen, some express neither or both, the intensity
of expression varies, and so on. This shows that
antigen expression does not breed true: On the
contrary it not only changes as cells divide but the
changes are probably reversible. Further evidence
for this was obtained by Chang & Taylor-
Papadimitriou (1982) who stained human milk cells
with antibody HMFG1 and separated positive from
negative by fluorescence-activated cell sorting. In
culture some of the positive cells became negative
and vice versa. The constant regeneration of a
typical pattern of heterogeneity in a clone strongly
suggests that it is controlled in some way.
Clones are not necessarily all identical, however.
When clones from cell lines were analysed
quantitatively they showed different overall antigen
content (Hand et al., 1983; Peterson et al., 1983).
Heterogeneity is notjust variation with the cell cycle
One possible explanation for heterogeneous
expression of antigens would be that a particular
antigen is expressed in a particular phase of the cell
cycle. This has been examined using tumour cell
lines, which grow rapidly enough for a significant
proportion of the cells to be dividing. The cells are
stained with the monoclonal antibody, and
simultaneously their DNA is stained with a
different fluorescence colour. The relationship
between DNA content, i.e. position in the cell cycle,
and antibody fluorescence is determined using a
flow cytometer (fluorescence-activated cell sorter).
Interpreting these experiments is complicated by
two considerations. First, as a cell traverses the cell
cycle it becomes two cells, so that cells entering
mitosis must have twice as much surface antigen as
cells that have just divided and that are therefore
among the cells in Go+G1 phase of the cycle.
(Apparently the problem of halving both the
surface and volume of a cell at division is solved by
reducing the number of microvilli; Pasternak, 1981).
Average antigen expression must increase somewhat
between GO+G1 and M, possibly up to two-fold.
The second problem is very important: an antigen
could be expressed by a population of cells that
divides much more rapidly than the antigen-
negative population. A high proportion of antigen-
positive cells will then be in S +G2+M phases of
the cell cycle, while only a few of the antigen-
negative cells would be. This will result in brighter
average fluorescence being found in S +G2 +M
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phases of the cell cycle. The reverse is equally
possible, where the antigen-bearing population
divides more slowly than the remaining cells. It
would be very interesting if expression of an
antigen correlated with a high division rate, as we
might then have a monoclonal antibody that would
identify cells capable of division.
Using two monoclonal antibodies to melanomas,
Burchiel et al. (1982) found that antigen expression
was very heterogeneous throughout the cell cycle,
and increase in cell surface probably accounted for
the modest increase in antigen expression between
G1 and G2 phases. We obtained similar results
using monoclonal antibodies to three distinct
epithelial antigens (Edwards et al., 1984b). For two
other antibodies Kufe et al. (1983) reported a
preferential expression in S+G2/M phases, but
whether this was due to size increase is not clear. A
surprising feature of their data is a lack of
heterogeneity in antigen expression among the cells
that were positive. Other antigens show a wide
range of intensity of expression. In any case,
heterogeneity clearly cannot in general be ascribed
to variations with the cell cycle.
The chemistry ofantigenic heterogeneity
Cell-surface molecules are generally glycoprotein or
glycolipid, so the molecular grouping or "epitope"
that a monoclonal antibody binds to could be a
protein part of a glycoprotein, a hybrid structure
made up of protein and carbohydrate, or pure
carbohydrate on either a glycolipid or a
glycoprotein molecule. It is beginning to look as
though most, perhaps almost all existing
monoclonal antibodies to surface antigens of
epithelial tumours bind to carbohydrate, or hybrid
structures, rather than to protein structures. This is
demonstrated by showing that the binding is lost
after treatment with glycosidases or in the presence
of competing saccharide fragments. For example,
several groups have raised monoclonal antibodies
with some specificity for lung tumours, that bind to
the carbohydrate structure lacto-N-fucopentaose
III, which may occur on glycoprotein or glycolipid
(Huang et al., 1983). Other antibodies to lung bind
to carbohydrates (Iwaki et al., 1982; Lloyd et al.,
1983). At least three monoclonal antibodies raised
to gastrointestinal carcinomas bind to distinct
carbohydrate structures (Abe et al., 1983;
Brockhaus et al., 1981; Magnani et al., 1983). A
number of the antibodies to epithelial cells bind to
a (class of) high molecular-weight glycoprotein(s)
that have been named epithelial membrane antigen
(Ormerod et al., 1983) or PASO (Shimizu &
Yamauchi, 1982) and at least some of them react
with carbohydrate-containing parts of this
molecule(s) (Burchell et al., 1983; Hilkens et al.,
1984; Ormerod et al., 1984a, b; Ellis et al., 1984).
Other antibodies to breast raised using milk-fat
globule membrane as immunogen bind to other
carbohydrate structures (Canevari et al., 1983; Gooi
et al., 1983; Hilkens et al., 1984; Mcllhinney,
R.A.J., personal communication). Several anti-
bodies to melanomas have been identified as anti-
ganglioside (Cahan et al., 1982; Nudelman et al.,
1982; Pukel et al., 1982). Unfortunately comparable
methods are not available to identify antibodies to
purely protein structures on the cell surface, so the
apparent absence of antibodies shown to be anti-
protein may be misleading. Nevertheless, most
antigenic heterogeneity that has been described
probably represents differences in carbohydrate
structures between cells. This has lead to the view
that the cells display the same proteins but vary the
carbohydrate groupings on them, and that if we
raised monoclonal antibodies to the protein
portions of the glycoproteins they would bind to all
the tumour cells. However, it is also possible that
different cells are expressing different glycoproteins.
Protein structures can, at least sometimes, be
expressed heterogeneously. When the cytoplasm of
endocrine tumours is stained with antisera to
polypeptide hormones, and even serotinin,
heterogeneous staining is often seen (e.g. Polak &
Bloom, 1983; McDowell et al., 1981), and similarly
staining of normal epithelia and carcinomas for
cytokeratins, a group of cytoplasmic proteins that
are almost certainly not glycosylated, can be
heterogeneous (Gatter & Mason, 1982; Evans,
1983; Ramaekers et al., 1983). Tumour cells may
express the histocompatibility antigens HLA-A,-B,-
C and DR heterogeneously (see below), and
presumably the antibodies used to detect these
antigens bind to protein portions of the molecules.
Finally, it is also possible that all the cells have
the antigen on their surface but that the structure
recognised by a given antibody may only be
accessible on certain cells. There is evidence that
accessibility can determine the observed expression
of antigens (Willison et al., 1982).
Why do so many monoclonal antibodies that
have been raised to epithelial antigens recognise
carbohydrate epitopes? Is it that carbohydrate
antigens stimulate a large number of B cells or that
they are particularly abundant, robust and
accessible components of immunising material? Are
only carbohydrate structures accessible on the
surface of epithelial cells, other structures being
buried inside a dense glycocalyx? Are carbohydrate
structures so much more abundant and accessible
than protein groupings that bivalent binding by
low-affinity antibody gives good staining, while
much higher-affinity antibody is required to stain
protein structures because only monovalent binding
is possible? Have we inadvertently selected againstANTIGENIC HETEROGENEITY OF TUMOUR CELLS 155
antibodies to protein epitopes because they tend not
to stain fixed tissue in sections?
Some laboratories are now raising monoclonal
antibodies to glycoproteins that have been stripped
of their carbohydrates. It will be interesting to see
whether or not antigenic heterogeneity will come to
be seen, in retrospect, to have been an artefact of
the ease with which monoclonal antibodies can be
obtained to carbohydrate epitopes.
Anomalous expression ofmajor histocompatibility
antigens
Among the antigens studied on tumours with
monoclonal antibodies are the histocompatibility
antigens HLA-A,-B,-C and HLA-DR, and IB2-
microglobulin, which is associated with the HLA-
A,-B,-C antigens in the cell membrane. These
antigens play a crucial role in initiating and
controlling immune responses and in directing the
killing of target cells by cytotoxic T cells (Klein,
1979).
A priori, we might have expected that HLA-A,
-B,-C and /32-microglobulin would be on all cells. In
fact they are expressed, apparently uniformly, by
normal breast and colon epithelium, but are absent,
or present heterogeneously, in about half of
malignant breast tumours (Fleming et al., 1981;
Natali et al., 1983). They were expressed normally
in fourteen of fifteen colonic carcinomas but one
showed only patchy expression (Daar & Fabre,
1983). f32-microglobulin seems to follow HLA-A,
-B,-C (Weiss et al., 1981) except that Natali et al.
(1983) found some discrepancies between staining
for f2-microglobulin and HLA-A,-B,-C in breast
tumours. However, not all cells express HLA-A,-B,
-C, at levels detected by staining (Fleming et al.,
1981), and although HLA-A,-B,-C are positive on
most normal epithelial cells there might be some
heterogeneity, a few inconspicuous cells being
almost negative.
HLA-DR is expressed by certain cells of the
immune system, and is absent from the majority of
other cell types. It might have been expected to be
absent from most epithelial cells and melanocytes,
but it was found on melanomas and some
carcinomas, suggesting that it might be "switched
on" in tumours. However, the picture is not that
simple. It was expressed by about half the
colorectal carcinomas examined and showed typical
patchy heterogeneity (Daar & Fabre, 1983).
Heterogeneous expression seemed to correlate with
relatively good differentiation (Rognum et al.,
1983). Normal colon epithelium is usually negative
when stained for HLA-DR, but positive areas of
apparently normal histology were found associated
with tumour, and colon epithelium can express
HLA-DR in graft versus host disease, and so can
skin (Mason et al., 1981; Lampert et al., 1981).
Melanomas express HLA-DR heterogeneously,
while normal mature melanocytes apparently do
not (Thompson et al., 1982 and numerous studies
of monoclonal antibodies to melanoma cell lines)
but Houghton et al. (1983) suggest that immature
normal melanocytes do have HLA-DR. Breast, on
the other hand, normally expresses HLA-DR, and
does so heterogeneously, and the antigen is
particularly abundant in lactating epithelium and
milk (Newman et al., 1980; Natali et al., 1983).
Carcinomas of the breast apparently usually express
less HLA-DR than the normal, and do so
heterogeneously (Natali et al., 1983).
How should we interpret these observations?
HLA-A,-B,-C and DR are important recognition
molecules for the immune system so variations in
their expression in tumours have attracted attention
and speculation. The origin of their variable
expression is presumably merely another example of
the variable and usually heterogeneous expression
of antigens in these tissues. Its only special
significance might be a consequential effect on the
ability of the immune system to interact with these
cells, but since normal tissues display variable levels
of the antigens it seems unlikely, for example, to be
a mechanism for tumours to escape immune
surveillance.
Interpretation
What is the biological significance ofantigenic
heterogeneity?
The crucial biological question is whether the cells
expressing different antigens (i) are in different
states of differentiation or maturity or biochemical
activity, for example, or (ii) are essentially identical,
the variations in antigen expression being quite
unrelated to the cell's general biochemistry. At
present there are arguments for both these
alternatives and no answer can be given.
A good case can be made that antigen expression
relates to the differentiation or biochemical state of
the cell in some way. In other systems we have
come to associate specific antigen expression with
differentiation: for example T and B lymphocytes
and subsets of T lymphocytes bear various
characteristic antigens. This can be true even when
the only differences between the cells are in
carbohydrate structures: differences in glycosylation
can be correlated with differentiation - for example
the expression of certain carbohydrate antigens
occurs at specific stages in embryonic development
(Shevinsky et al., 1982) and a family of antigens
that distinguishes cell types and stages of
development in the nervous system has been shown
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to be made up of the same polypeptide(s) with
different glycosylation (Rougon et al., 1982). The
regular patterns of expression of antigen in some
epithelia suggest that the cells expressing different
antigens may be in different states of
differentiation, or in in different stages of maturity.
In particular, the steady change of antigen
expression between the bottom and top of the
crypts of the colon corresponds to the maturation
of the cells (Figures 3-5; Finan et al., 1982; Daar &
Fabre, 1983; Edwards & Brooks, 1984). If surface
antigen expression does correlate with the state of
the cell we have some very interesting new insights
into the differentiation and organisation of normal
epithelia.
In some cases, it seems almost obvious that
antigen expression in tumours correlates with
differentiation. We are accustomed to leukaemias
expressing surface antigens characteristic of a
normal cell in a particular state of differentiation,
and a similar scheme has been drawn up for
melanomas (Houghton et al., 1983). In squamous
epithelia the expression of particular keratins is
characteristic of stages in the life history of a cell.
Keratin expression can be heterogeneous between
cells in squamous carcinomas (Evans, 1983), and it
seems very likely that it reflects the state of
differentiation of the tumour cells.
On the other hand, the heterogeneity of antigen
expression in permanent cell lines and in small
clones, and the absence of obvious correlation with
morphology, perhaps suggests that the
heterogeneity is merely a randomisation of surface
structures, unrelated to other properties of the cell.
It is possible to imagine functions for this. For
example, it could protect against pathogen attack: a
given pathogen would perhaps only be able to
attack cells bearing particular carbohydrate groups.
Alternatively, varying the glycosylation of cells
might be a way of regulating the organisation of
the epithelium through cell-cell interactions
(Edwards. 1978).
Implications
Possible implicationsfor tumour cell heterogeneity in
general
It follows that at least some of the heterogeneity in
surface antigen expression by the cells of a tumour
arises from a normal property of epithelia and is
rapidly regenerated in the progeny of a cell. This
conflicts with some conventional views about
tumour cell heterogeneity. It is well known that the
cells of a tumour are often heterogeneous in various
ways - in morphology, response to drugs, and so
on (reviewed in Heppner, 1984; Owens et al., 1982;
Woodruff, 1983) but the dramatic variability in the
expression of antigens between cells has only been
fully realised with the staining of sections of
tumours with monoclonal antibodies. Heterogeneity
has often been assumed, explicitly or implicitly, to
be due to irreversible genetic changes (e.g. Nowell,
1976; Kerbel, 1979; Fidler & Hart, 1982; Nicolson,
1982) because they clearly do occur- for example
karyotypically and morphologically variant strains
can be isolated (Heppner, 1979; Owens et al., 1982).
Nowell (1976) has suggested that as a tumour
progresses it evolves a tendency to genetic
variability which enables it to evolve rapidly and
survive in spite of varying selective pressures. While
there is no doubt that permanent genetic changes
occur, the regeneration of antigenic heterogeneity in
clones suggests that heterogeneity arises by
reversible variations in gene expression as well as
irreversible differentiation or by genetic changes:
That is, heterogeneity can be phenotypic as well as
genotypic.
Heterogeneity of cells has often been studied by
isolating clones from a tumour (e.g. Heppner, 1979;
Fidler & Hart, 1982; Owens et al., 1982). The
regeneration of heterogeneity in clones shows that
this approach is inadequate to capture the full
heterogeneity of a tumour (quite apart from the
problem of drift in the properties of cloned lines in
the long term (Neri & Nicolson, 1981)). Many
studies of tumour heterogeneity have been
concerned with metastasis - few cells from a
tumour form metastases, and attempts have been
made to see whether there are sub-populations of
tumour cells that metastasize more efficiently
(Fidler & Hart, 1982). Heterogeneity of the cell
surface is particularly important in this context as it
is likely to affect the ability of cells both to invade
and to seed in metastatic sites. Clones have been
grown from tumours to see if they have varied
metastatic potential, usually measured as the ability
to seed and form colonies in particular organs.
Overall the results have been equivocal, and have
never been dramatic: clones do not differ by orders
of magnitude in their abilities to seed and form
colonies (Fidler & Hart, 1982; Nicolson, 1982;
Poste, 1982; Weiss et al., 1983). We can now raise
the possibility that cells with different surface
properties do indeed have different abilities to
metastasize, but that attempts to identify clones
with high or low metastatic potential have
foundered because heterogeneity of surface
properties is regenerated rapidly in the clones,
before they can be tested.
Our tendency to think that heterogeneity in the
cells of a tumour arises from permanent changes,
whether in genes or gene expression, reflects our
tendency to think that a clone of cells isANTIGENIC HETEROGENEITY OF TUMOUR CELLS 157
homogeneous. As also noted by Heppner (1984)
each of us is a clone of cells.
Clinical application ofmonoclonal antibodies
Is there any way round the problem that antigenic
heterogeneity poses for the development of magic-
bullet therapy with monoclonal antibodies other
than trying to raise antibodies to homogeneously-
expressed antigens? If antigen expression correlates
with the differentiated state of a cell, a subset
(possibly rare) of tumour cells expressing a
particular antigen may have the greatest capacity
for division or metastasis, so that antibodies to that
antigen might be adequate for therapy. The absence
so far of any clear relation between antigen
expression and cell proliferation is therefore
disappointing.
Antibodies to heterogeneously-expressed antigens
may still be effective in therapy, particularly if used
as mixtures. If heterogeneity is constantly
regenerated as cells grow, it may be less of a
problem than it would seem at first sight. Suppose
80% of cells in a tumour are killed by an antibody,
leaving 20%. If heterogeneity is regenerated, these
20% would grow to give not a resistant tumour but
one with nearly 80% sensitive cells. In the long
term, more resistant cells may be selected for, but in
the medium term the effect might be useful for a
slow-growing tumour such as breast carcinoma.
Flow cytometry data (Burchiel et al., 1982;
Edwards et al., 1984b) show that heterogeneity is
not a matter of cells being negative or positive, but
rather of a continuous range of antigen expression.
The proportion of cells that would be unaffected by
an antibody-directed therapy would therefore
depend on the killing efficiency of the method. A
toxin-antibody conjugate might kill cells that
immunocytochemical staining methods would judge
to be antigen-negative. It is encouraging that
Capone et al. (1984) have reported some success in
treating tumours with antibodies to heterogeneously-
expressed antigens in a model system - they were
able to reduce the size of established human breast
tumours that had been xenografted onto nude mice,
by injecting antibody. The degree of response
seemed to correlate with overall abundance of
antigen in the tumour (Capone et al., 1984).
Cell-surface heterogeneity may be a less serious
problem in diagnosis. If 50% or even 20% of cells
react with an antibody they will usually be detected
in a section or smear. For example, Dearnaley et al.
(1981) have shown that tumour cells can be
detected in marrow biopsies from breast cancer
patients, at a much lower level than can be detected
by morphology alone, by staining with antibody,
even though the antibodies used do not stain all the
tumour cells.
Heterogeneity of antigen expression does,
however, makes it difficult to score the staining of a
tumour with a particular monoclonal antibody -
see for example Figure 3 - so that it may be
difficult to extract any clear-cut prognostic
significance from the expression of a particular
antigen by a tumour. Usually, a tumour cannot
simply be scored as positive or negative for
expression of an antigen, nor can most tumours be
scored for the way an antigen is expressed, i.e.
cytoplasmically, on the luminal membrane, on the
membrane all around the cells, and so on, because
different areas or cells of a given tumour will give a
different score. However, we may come to recognise
the significant features - Wilkinson et al. (1984)
have developed a scoring system to try and analyse
staining by taking these problems into account.
They obtained both encouraging and discouraging
results. By staining with antibody HMFG1 they
claim to be able to classify 20% of patients into
groups with either strikingly good or strikingly bad
prognosis, respectively those with high staining of
extracellular material or no staining of the tumour
at all. However, 80% of patients showed other
patterns of staining which could not be related to
prognosis, and staining with antibody HMFG2,
which generally stains tumours more than normal
tissue, could not be related to prognosis at all.
Others are attempting to classify tumours according
to which of several antigens they express (Hand et
al., 1983; Rasmussen et al., 1982) but assessments
of prognostic significance are not yet available.
Conclusion
The present generation of monoclonal antibodies to
human epithelial tumours almost all bind to only
some of the cells in a tumour, as judged by staining
methods. Several questions now need to be fully
answered: does antigen expression reflect
differentiation or not? Is heterogeneity a property
of carbohydrate structures alone? Will it be possible
to make a second generation of antibodies to
homogeneously-expressed antigens? Will antibodies
to heterogeneously-expressed antigens nevertheless
be effective in therapy and diagnosis?
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